观察者网消息，美欧关税谈判进入关键时刻，特朗普突然抛出30%的关税将欧盟逼入墙角。而一度放狠话 反制的欧盟，很快又"软"了。 当地时间7月13日，欧盟委员会主席冯德莱恩表示，决定推迟原定于7月15日对价值210亿欧元的美国产品 加征报复性关税，以争取通过谈判达成协议。她称，欧盟一直明确表示倾向于与美国通过协商达成解决方 案，这一立场依然不变。她还强调，欧盟将"继续准备"第二轮反制措施清单，但不会动用"反胁迫机制"。 法国曾多次呼吁动用这一工具反制美国关税。 知情人士表示，欧盟计划与包括加拿大和日本在内的国家进行接触，可能会讨论协调应对措施。不过一些 欧洲商业组织和政界人士批评冯德莱恩应对策略软弱，认为一旦特朗普对欧关税正式落地，冯德莱恩 将"彻底失败"。 冯德莱恩13日对记者表示，原定当地时间7月15日生效的对美国进口产品（包括鸡肉、摩托车和服装等） 征税措施将被推迟至"8月初"实施。 "我们一直明确表示，希望与美方通过谈判解决问题，这一立场依然不变。" 她补充道："与此同时，我们将继续准备更多反制措施，以便做好万全准备。" 资料图：欧盟委员会主席冯德莱恩 彭博社13日援引知情人士的话称，欧盟正准备加强与其他 ...

公司公告汇总 三星医疗第六届董事会第二十四次会议和第六届监事会第十九次会议审议通过了关于回购注销部分激励 对象已获授但尚未解除限售的第四期、第五期限制性股票的议案。鉴于5名激励对象因离职已不符合激 励条件，公司将回购注销其已获授但尚未解除限售的41,800股限制性股票。回购价格分别为：第四期首 次授予的限制性股票5.59元/股，第四期预留授予的限制性股票4.75元/股，第五期首次授予的限制性股 票5.35元/股，第五期预留授予的限制性股票4.75元/股。回购资金总额为207,694元，全部为公司自有资 金。回购完毕后，公司将向中国证券登记结算有限责任公司上海分公司申请该部分股票的注销，注销完 成后，公司注册资本将由1,411,006,571元减少至1,410,964,771元。监事会和上海市锦天城律师事务所均 发表了同意意见，认为本次回购注销符合相关法律法规和公司规定。公司债权人自接到公司通知起30日 内、未接到通知者自本公告披露之日起45日内，均有权凭有效债权文件及相关凭证要求公司清偿债务或 者提供相应担保。债权申报所需材料包括证明债权债务关系存在的合同、协议及其他凭证的原件及复印 件等。债权申报登记地点为 ...

背后藏着的是一个让所有人都没料到的秘密， 美国的镍矿需求，恰好是中国最大的弱点...... 印尼的这一转变来得太快，也太惊人， 不得不说，面对特朗普的关税大棒， 越南这一跪起到了"表率"的作用， 当地时间7月5日，印尼方面传来消息，将很快与美国签署一份总额达340亿美元的贸易协议。 这个与中国有着深厚经济合作的国家，突然转身向美国投降， 7月3日，印尼宣布与美国签署了一项总额高达340亿美元的贸易协议， 涉及范围之广、金额之大，让所有人都瞪大了眼睛。 协议内容包括从美国采购大量天然气、农产品、电子产品、机械、医疗设备等， 同时印尼还承诺对美国的1700多种商品实施接近零关税。 这哪里还是贸易谈判，更像是印尼向美国递上的"投名状" 同时印尼还宣布将放宽对美国企业的投资限制，给予他们更为优惠的待遇。 很显然印尼对美国敞开大门，这一切的背后，究竟是因为什么呢？ 细细分析印尼的选择，实际上并不难理解。 在特朗普政府挥舞着"对等关税"大棒的威胁下，印尼的经济压力可想而知， 作为一个资源大国，印尼的经济依赖于其丰富的自然资源， 特别是矿产资源，镍矿便是其中的重头戏。 全球新能源产业对镍的需求日益增加，印尼正是全球镍矿的主 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight increase of 0.39% recently, reflecting the overall performance of listed companies in the healthcare sector [1] Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services is currently at 13,682.83 points with a trading volume of 18.089 billion [1] - Over the past month, the index has decreased by 0.83%, while it has increased by 2.95% over the last three months, and has seen a year-to-date decline of 0.43% [1] Group 2: Index Composition - The index is composed of listed companies that correspond to the healthcare theme, with a base date of December 31, 2004, set at 1,000.0 points [1] - The top ten weighted companies in the index include: Mindray Medical (9.44%), United Imaging (8.04%), Aier Eye Hospital (7.55%), Aimeike (3.41%), Huatai Medical (3.23%), New Industry (2.81%), Yuyue Medical (2.7%), Lepu Medical (2.54%), Meinian Onehealth (2.05%), and Shandong Pharmaceutical Glass (1.91%) [1] Group 3: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.09%) and the Shanghai Stock Exchange (39.91%) [1] - The healthcare sector accounts for 100% of the index's holdings [1] Group 4: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple financial institutions [2]

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/6/27-2025/7/10） 血液透析设备迎来集采 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 相关报告 行 业 周 报 行 业 研 究 证 券 研 究 报 告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 7 月 11 日 分析师： ...

2025年7月9日，美国医疗科技公司 Neuros Medical 宣布， 已完成规模达5600万美元（约合人民币4.02亿元）的D轮融资。 本轮融资由EQT Life Sciences领投，US Venture Partners、Amzak Health、Osage University Partners、Sectoral Asset Management、Aperture Venture Partners等现有投资者亦参与跟投。 此次融资不仅为Neuros Medical在美国市场全面商业化其创新产品Altius直接电神经刺激系统（Direct Electrical Nerve Stimulation System）提供了坚实的资金支持，也 再次凸显了资本市场对非阿片类疼痛治疗技术的高度关注。 # 融资用途 # 技术创新 全面商业化 ： 加速Altius系统在美国市场的推广，包括组建更完善的销售团队、建立分销网络、加强临床医生教育与培训。 技术优化与新适应症探索 ： 进一步完善Altius系统的人因工程设计，提升产品易用性，并探索其在其他类型慢性神经痛（如神经病理性疼痛、糖尿病周围神 经病变等）领域的应用 ...

Core Points - The Shanghai Stock Exchange Science and Technology Innovation Board Medical Index (科创医疗) reported a value of 741.74 points, showing a trend of opening lower and then rising [1] - The index has increased by 0.39% over the past month, 3.47% over the past three months, and 2.28% year-to-date [2] - The index consists of no more than 30 listed companies in the medical field selected from the Science and Technology Innovation Board, reflecting the overall performance of medical listed companies [2] Index Composition - The top ten weighted companies in the index are: - 惠泰医疗 (10.85%) - 联影医疗 (9.4%) - 热景生物 (7.71%) - 奕瑞科技 (6.88%) - 爱博医疗 (6.07%) - 南微医学 (5.08%) - 圣湘生物 (4.63%) - 心脉医疗 (4.45%) - 海尔生物 (3.82%) - 亚辉龙 (3.27%) [2] Market and Sector Breakdown - The index is fully composed of companies listed on the Shanghai Stock Exchange, with a sector breakdown of: - Medical consumables: 42.55% - Medical devices: 29.61% - In-vitro diagnostics: 27.84% [3] - The index samples are adjusted quarterly, with adjustments occurring in March, June, September, and December [3]

-2025 下半年医药产业政策展望 摘要: 2025.07.10 保基本、强创新 慧博投研",请勿外传! 产业研究中心 | CR | 丁丹(分析师) | | --- | --- | | 8 | 021-38676666 | | 登记编号 | S0880514030001 | | ર | 贺文斌(分析师) | | 8 | 021-38676666 | | 登记编号 | S0880525040034 | | S | 张拓(分析师) | | 2 | 021-38676666 | | 登记编号 | S0880523090003 | 请务必阅读正文之后的免责条款部分 1 of 21 o 政策主线为保基本和强创新。从近期顶层设计政策和地方、部委具体文件 发布、政策实施看,整体沿着"保基本、强创新"两条主线。1)保基本一 一保障人民群众基本的医疗需求,通过医保目录等措施提升医疗产品和服 务的可及性,通过集采降价等措施匹配可支付性,同时通过纠风整顿等措 施规范医疗市场、保障政策实施效果。2)强创新 -- 加强创新,从产品评 审、医保准入、多元支付、国际推广、融资等全链条支持创新,获取产业 升级和满足更多未被满足临床需求的经济 ...

Core Insights - Researchers at Johns Hopkins University have developed an AI-powered robot capable of autonomously performing gallbladder surgeries, marking a significant advancement in automated healthcare [1][2] - The SRT-H robot can make independent judgments and decisions during surgery, akin to self-driving cars that can navigate various situations [1] - The robot achieved a 100% success rate in trial surgeries, although it took longer than human surgeons to complete the procedures [2] Group 1: Technological Advancements - The SRT-H robot utilizes an AI framework trained on videos of surgeons performing gallbladder surgeries on pigs, allowing it to understand surgical procedures [1] - The robot demonstrated the ability to perform complex tasks such as grasping, cutting, and decision-making in real-time during surgeries [1] Group 2: Market Implications - The global surgical robot market is approaching $10 billion, with an estimated 2.7 million robot-assisted surgeries performed worldwide in 2024 [2] - The introduction of autonomous surgical robots could address the shortage of surgeons and reduce human error, providing stable and high-quality medical services in underserved areas [2]

Core Insights - The article highlights the successful production of the 35,000th detector at GE Healthcare's Beijing imaging equipment manufacturing base, emphasizing the importance of the detector in determining CT imaging quality [1][3]. Group 1: Detector Technology - The detector consists of three critical components: the scintillation crystal layer (captures X-rays), the photoconversion layer (converts signals), and the electronic circuit layer (processes data), all requiring micron-level alignment for optimal performance [3][5]. - The scintillation crystal, a key material for the detector, was previously a significant barrier for domestic high-end imaging equipment, but a partnership with Sichuan Meishan Boya New Materials Company has led to the successful validation of L(Y)SO scintillation crystals [3][5]. Group 2: Production Efficiency - Each CT detector requires 416 matching chip units, and variations in crystal growth direction and doping uniformity can lead to performance discrepancies; thus, precise matching is essential to avoid imaging errors [5]. - The use of AI algorithms has significantly reduced the traditional manual matching process from 5 hours to just 10 minutes, allowing for the selection of complementary chip combinations to meet diverse equipment needs while ensuring imaging quality [5]. - An AI quality inspector, trained on over 600,000 production experiences, can identify over 90% of raw material quality issues early in the production process, minimizing waste caused by traditional manufacturing defects [5].